Bristol-Myers Squibb (NYSE:BMY) reported Q2 EPS of $1.93, $0.13 better than the analyst estimate of $1.80. Revenue for the quarter came in at $11.89 billion versus the consensus estimate of $11.44 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2022 EPS of $7.44-$7.74, versus the consensus of $7.46. Bristol-Myers Squibb sees FY2022 revenue of $46 billion, versus the consensus of $46.24 billion.